Precycle
Laufzeit: 01.01.2017 - 31.12.2025
imported
Kurzfassung
Multicenter, randomized phase IV intergroup trial to evaluate the impact of e Health-based patient reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative advanced or metastatic breast cancer treated with Palbociclib and an aromatase inhibitor- or Palbociclib and Fulvestrant
Veröffentlichungen
- Harbeck, Nadia; Fasching, Peter A.; Wuerstlein, Rachel et al.
- CANKADO PRO-React eHealth support in patients with HR+HER2-metastatic breast cancer receiving palbociclib and endocrine therapy and the affect on time to deterioration of quality of life: Primary outcome analysis of the multicenter randomized PreCycle trial
- Degenhardt, Tom; Fasching, Peter A.; Lueftner, Diana et al.
- PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant
- Harbeck, N.; Fasching, P. A.; Wuerstlein, R. et al.
- Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HRD HER2L metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial
